Phosphate binders in chronic kidney disease: a systematic review of recent data

Journal of Nephrology

Volumn 29, Issue 3, 2016, Pages 329-340

  Floege, Jürgen ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Adherence; CKD; Phosphate binder; Phosphate transport

Indexed keywords

ALUMINUM CONTAINING PHOSPHATE BINDER; BIXALOMER; CALCIUM ACETATE; CALCIUM CARBONATE; CHITOSAN; COLESTILAN; FERRIC CITRATE; FIBROBLAST GROWTH FACTOR 23; LANTHANUM CARBONATE; MAGNESIUM; MAGNESIUM CONTAINING PHOSPHATE BINDER; MAGNESIUM DERIVATIVE; NICOTINAMIDE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; SUCROFERRIC OXYHYDROXIDE; UNCLASSIFIED DRUG; DRUG COMBINATION; FERRIC ION; LANTHANUM; POLYAMINE; SUCROSE;

BLOOD VESSEL CALCIFICATION; CHEWING GUM; CHRONIC KIDNEY DISEASE; DIALYSIS; HEART ARRHYTHMIA; HEMODIALYSIS; HUMAN; HYPERMAGNESEMIA; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; OSTEOPOROSIS; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PHOSPHATURIA; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; DRUG COMBINATION; HYPERPHOSPHATEMIA; METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

DRUG COMBINATIONS; FERRIC COMPOUNDS; HUMANS; HYPERPHOSPHATEMIA; LANTHANUM; PHOSPHATES; POLYAMINES; RENAL INSUFFICIENCY, CHRONIC; SEVELAMER; SUCROSE;

EID: 84970007043     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-016-0266-9     Document Type: Review

References (121)

1. Tonelli M, Pannu N, Manns B (2010) Oral phosphate binders in patients with kidney failure. N Engl J Med 362:1312–1324
2. Mehrotra R, Peralta CA, Chen SC, Li S, Sachs M, Shah A, Norris K, Saab G, Whaley-Connell A, Kestenbaum B, McCullough PA, Kidney early evaluation program I (2013) No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. Kidney Int 84:989–997
3. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM (2011) Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 109:697–711
4. Abbasian N, Burton JO, Herbert KE, Tregunna BE, Brown JR, Ghaderi-Najafabadi M, Brunskill NJ, Goodall AH, Bevington A (2015) Hyperphosphatemia, phosphoprotein phosphatases, and microparticle release in vascular endothelial cells. J Am Soc Nephrol 26:2152–2162
5. Shobeiri N, Adams MA, Holden RM (2014) Phosphate: an old bone molecule but new cardiovascular risk factor. Br J Clin Pharmacol 77:39–54
6. Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6:913–921
7. Nagel CJ, Casal MC, Lindley E, Rogers S, Pancirova J, Kernc J, Copley JB, Fouque D (2014) Management of hyperphosphataemia: practices and perspectives amongst the renal care community. J Ren Care 40:230–238
8. Cupisti A, Benini O, Ferretti V, Gianfaldoni D, Kalantar-Zadeh K (2012) Novel differential measurement of natural and added phosphorus in cooked ham with or without preservatives. J Ren Nutr 22:533–540
9. Penne EL, van der Weerd NC, van den Dorpel MA, Grooteman MP, Levesque R, Nube MJ, Bots ML, Blankestijn PJ, ter Wee PM, Investigators C (2010) Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST). Am J Kidney Dis 55:77–87
10. Kuhlmann MK (2010) Phosphate elimination in modalities of hemodialysis and peritoneal dialysis. Blood Purif 29:137–144
11. Daugirdas JT, Chertow GM, Larive B, Pierratos A, Greene T, Ayus JC, Kendrick CA, James SH, Miller BW, Schulman G, Salusky IB, Kliger AS, Frequent Hemodialysis Network Trial G (2012) Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. J Am Soc Nephrol 23:727–738
12. Movilli E, Camerini C, Gaggia P, Poiatti P, Pola A, Viola BF, Zubani R, Jeannin G, Cancarini G (2011) Effect of post-dilutional on-line haemodiafiltration on serum calcium, phosphate and parathyroid hormone concentrations in uraemic patients. Nephrol Dial Transpl 26:4032–4037
13. Locatelli F, Altieri P, Andrulli S, Sau G, Bolasco P, Pedrini LA, Basile C, David S, Gazzanelli L, Tampieri G, Isola E, Marzolla O, Memoli B, Ganadu M, Reina E, Bertoli S, Ferrara R, Casu D, Logias F, Tarchini R, Mattana G, Passaghe M, Fundoni G, Villa G, Di Iorio BR, Pontoriero G, Zoccali C (2014) Phosphate levels in patients treated with low-flux haemodialysis, pre-dilution haemofiltration and haemodiafiltration: post hoc analysis of a multicentre, randomized and controlled trial. Nephrol Dial Transpl 29:1239–1246
14. Zitt E, Fouque D, Jacobson SH, Malberti F, Ryba M, Urena P, Rix M, Dehmel B, Manamley N, Vervloet M (2013) Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction. Clin Kidney J 6:287–294
15. Denburg MR, Kumar J, Jemielita T, Brooks ER, Skversky A, Portale AA, Salusky IB, Warady BA, Furth SL, Leonard MB (2015) Fracture burden and risk factors in childhood CKD: results from the CKiD cohort study. J Am Soc Nephrol ASN-2015020152 [Epub ahead of print]
16. Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K (2010) Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis 56:842–851
17. Cannata-Andia JB, Fernandez-Martin JL, Locatelli F, London G, Gorriz JL, Floege J, Ketteler M, Ferreira A, Covic A, Rutkowski B, Memmos D, Bos WJ, Teplan V, Nagy J, Tielemans C, Verbeelen D, Goldsmith D, Kramar R, Martin PY, Wuthrich RP, Pavlovic D, Benedik M, Sanchez JE, Martinez-Camblor P, Naves-Diaz M, Carrero JJ, Zoccali C (2013) Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 84:998–1008
18. Lopes AA, Tong L, Thumma J, Li Y, Fuller DS, Morgenstern H, Bommer J, Kerr PG, Tentori F, Akiba T, Gillespie BW, Robinson BM, Port FK, Pisoni RL (2012) Phosphate binder use and mortality among hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 60:90–101
19. Smith ER (2014) The use of fibroblast growth factor 23 testing in patients with kidney disease. Clin J Am Soc Nephrol 9:1283–1303
20. Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drueke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J (2015) Evaluation of cinacalcet HTtLCETI: cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation 132:27–39
21. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM (2012) Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23:1407–1415
22. Van Camp YP, Vrijens B, Abraham I, Van Rompaey B, Elseviers MM (2014) Adherence to phosphate binders in hemodialysis patients: prevalence and determinants. J Nephrol 27(6):673–679
23. Covic A, Rastogi A (2013) Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrol 14:153
24. Wileman V, Farrington K, Wellsted D, Almond M, Davenport A, Chilcot J (2015) Medication beliefs are associated with phosphate binder non-adherence in hyperphosphatemic haemodialysis patients. Br J Health Psychol 20:563–578
25. Arenas MD, Malek T, Gil MT, Moledous A, Alvarez-Ude F, Reig-Ferrer A (2010) Challenge of phosphorus control in hemodialysis patients: a problem of adherence? J Nephrol 23:525–534
26. Fouque D, Horne R, Cozzolino M, Kalantar-Zadeh K (2014) Balancing nutrition and serum phosphorus in maintenance dialysis. Am J Kidney Dis 64:143–150
27. Shi YX, Fan XY, Han HJ, Wu QX, Di HJ, Hou YH, Zhao Y (2013) Effectiveness of a nurse-led intensive educational programme on chronic kidney failure patients with hyperphosphataemia: randomised controlled trial. J Clin Nurs 22:1189–1197
28. Van Camp YP, Huybrechts SA, Van Rompaey B, Elseviers MM (2012) Nurse-led education and counselling to enhance adherence to phosphate binders. J Clin Nurs 21:1304–1313
29. Umeukeje EM, Merighi JR, Browne T, Victoroff JN, Umanath K, Lewis JB, Ikizler TA, Wallston KA, Cavanaugh K (2015) Self-motivation is associated with phosphorus control in end-stage renal disease. J Ren Nutr 25:433–439
30. Jamal SA, Moe SM (2012) Calcium builds strong bones, and more is better–correct? Well, maybe not. Clin J Am Soc Nephrol 7:1877–1883
31. West SL, Swan VJ, Jamal SA (2010) Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population. Clin J Am Soc Nephrol 5(Suppl 1):S41–S47
32. Winkelmayer WC, Liu J, Kestenbaum B (2011) Comparative effectiveness of calcium-containing phosphate binders in incident US dialysis patients. Clin J Am Soc Nephrol 6:175–183
33. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, Lok CE, Fitchett D, Tsuyuki RT (2013) Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 382:1268–1277
34. Jean G, Lataillade D, Genet L, Legrand E, Kuentz F, Moreau-Gaudry X, Fouque D, investigators As (2011) Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study. Hemodial Int 15:485–492
35. Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM, Peacock M (2013) Oral calcium carbonate affects calcium but not phosphorus balance in stage 3–4 chronic kidney disease. Kidney Int 83:959–966
36. Spiegel DM, Brady K (2012) Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int 81:1116–1122
37. Shroff RC, McNair R, Skepper JN, Figg N, Schurgers LJ, Deanfield J, Rees L, Shanahan CM (2010) Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 21:103–112
38. Hutchison AJ, Wilkie M (2012) Use of magnesium as a drug in chronic kidney disease. Clin Kidney J 5:i62–i70
39. de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, Scholz C, Ponce P, Passlick-Deetjen J (2010) Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transpl 25:3707–3717
40. 3 in peritoneal dialysis patients—a cross-over pilot trial. Perit Dial Int 35:31–34
41. Tzanakis IP, Stamataki EE, Papadaki AN, Giannakis N, Damianakis NE, Oreopoulos DG (2014) Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study. Int Urol Nephrol 46:2199–2205
42. De Schutter TM, Behets GJ, Geryl H, Peter ME, Steppan S, Gundlach K, Passlick-Deetjen J, D’Haese PC, Neven E (2013) Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. Kidney Int 83:1109–1117
43. Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, Bellasi A, Investigators IS (2013) Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 62:771–778
44. Di Iorio B, Bellasi A, Russo D, Investigators IS (2012) Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 7:487–493
45. Iimori S, Mori Y, Akita W, Takada S, Kuyama T, Ohnishi T, Shikuma S, Ishigami J, Tajima M, Asai T, Okado T, Kuwahara M, Sasaki S, Tsukamoto Y (2012) Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study. Clin Exp Nephrol 16:930–937
46. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK (2007) Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72:1130–1137
47. Maizel J, Six I, Dupont S, Secq E, Dehedin B, Barreto FC, Benchitrit J, Poirot S, Slama M, Tribouilloy C, Choukroun G, Maziere JC, Drueke TB, Massy ZA (2013) Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure. Kidney Int 84:491–500
48. Kakuta T, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, Takahashi H, Hirawa N, Oogushi Y, Miyata T, Kobayashi H, Fukagawa M, Saito A (2011) Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 57:422–431
49. Chue CD, Townend JN, Moody WE, Zehnder D, Wall NA, Harper L, Edwards NC, Steeds RP, Ferro CJ (2013) Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol 24:842–852
50. Di Lullo L, Floccari F, Santoboni A, Barbera V, Rivera RF, Granata A, Morrone L, Russo D (2013) Progression of cardiac valve calcification and decline of renal function in CKD patients. J Nephrol 26:739–744
51. Lin YF, Chien CT, Kan WC, Chen YM, Chu TS, Hung KY, Tsai TJ, Wu KD, Wu MS (2011) Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study. Clin Drug Investig 31:257–267
52. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Donate-Correa J, Cazana-Perez V, Garcia-Perez J (2011) Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol 6:2272–2279
53. Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, Grosjean F, Woodward M, Striker GE (2012) Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol 7:934–942
54. Guida B, Cataldi M, Riccio E, Grumetto L, Pota A, Borrelli S, Memoli A, Barbato F, Argentino G, Salerno G, Memoli B (2013) Plasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a cross-sectional observational study. PLoS One 8:e73558
55. Brandenburg VM, Schlieper G, Heussen N, Holzmann S, Busch B, Evenepoel P, Vanholder R, Meijers B, Meert N, Fassbender WJ, Floege J, Jahnen-Dechent W, Ketteler M (2010) Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transpl 25:2672–2679
56. Takagi K, Masuda K, Yamazaki M, Kiyohara C, Itoh S, Wasaki M, Inoue H (2010) Metal ion and vitamin adsorption profiles of phosphate binder ion-exchange resins. Clin Nephrol 73:30–35
57. Pierce D, Hossack S, Poole L, Robinson A, Van Heusen H, Martin P, Smyth M (2011) The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. Nephrol Dial Transpl 26:1615–1621
58. Iovino M, Iovine N, Petrosino A, Giagulli VA, Licchelli B, Guastamacchia E, Triggiani V (2014) Sevelamer carbonate markedly reduces levothyroxine absorption. Endocr Metab Immune Disord Drug Targets 14:206–209
59. Fishbane S, Delmez J, Suki WN, Hariachar SK, Heaton J, Chasan-Taber S, Plone MA, Moe S (2010) A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. Am J Kidney Dis 55:307–315
60. Tzanno-Martins C, Biavo BM, Ferreira-Filho O, Ribeiro-Junior E, Joao-Luiz MV, Degaspari S, Scavone C, Kawamoto E (2014) Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis. Int J Immunopathol Pharmacol 27:25–35
61. Ito K, Takeshima A, Shishido K, Wakasa M, Kumata C, Matsuzaka K, Nakajima Y, Ogata H (2014) Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms. Ther Apher Dial 18(Suppl 2):19–23
62. Locatelli F, Dimkovic N, Spasovski G (2014) Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients. Expert Opin Pharmacother 15:1475–1488
63. Locatelli F, Dimkovic N, Pontoriero G, Spasovski G, Pljesa S, Kostic S, Manning A, Sano H, Nakajima S (2010) Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transpl 25:574–581
64. Locatelli F, Dimkovic N, Spasovski G (2013) Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial. Nephrol Dial Transpl 28:1874–1888
65. Locatelli F, Spasovski G, Dimkovic N, Wanner C, Dellanna F, Pontoriero G (2014) The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study. Nephrol Dial Transpl 29:1061–1073
66. Hertel J, Locatelli F, Spasovski G, Dimkovic N, Wanner C (2015) Randomized, double-blind, placebo-controlled, withdrawal study of colestilan after dose titration in chronic kidney disease dialysis patients with hyperphosphatemia. Nephron 130:229–238
67. Yubero-Serrano EM, Woodward M, Poretsky L, Vlassara H, Striker GE, Group AG-lS (2015) Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. Clin J Am Soc Nephrol 10:759–766
68. Vemuri N, Michelis MF, Matalon A (2011) Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study. BMC Nephrol 12:49
69. Dellanna F, Reichel H, Seibt F (2012) Efficacy and safety of lanthanum carbonate in German patients on dialysis. Clin Nephrol 78:382–390
70. Komaba H, Kakuta T, Suzuki H, Hida M, Suga T, Fukagawa M (2015) Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia. Nephrol Dial Transpl 30:107–114
71. Arenas MD, Rebollo P, Malek T, Moledous A, Gil MT, Alvarez-Ude F, Morales A, Cotilla E (2010) A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. J Nephrol 23:683–692
72. Takahara Y, Matsuda Y, Takahashi S, Shigematsu T (2014) Lanthanum carbonate study G: efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial. Clin Nephrol 82:181–190
73. Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, Martinez-Calero A, Navas V, Rodriguez M, Ortiz A (2011) Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol Dial Transpl 26:2567–2571
74. Urena-Torres P, Prie D, Keddad K, Preston P, Wilde P, Wan H, Copley JB (2014) Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial. BMC Nephrol 15:71
75. Zhang C, Wen J, Li Z, Fan J (2013) Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol 14:226
76. Nikolov IG, Joki N, Nguyen-Khoa T, Guerrera IC, Maizel J, Benchitrit J, Machado dos Reis L, Edelman A, Lacour B, Jorgetti V, Drueke TB, Massy ZA (2012) Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. Nephrol Dial Transpl 27:505–513
77. Toida T, Fukudome K, Fujimoto S, Yamada K, Sato Y, Chiyotanda S, Kitamura K (2012) Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Clin Nephrol 78:216–223
78. Ohtake T, Kobayashi S, Oka M, Furuya R, Iwagami M, Tsutsumi D, Mochida Y, Maesato K, Ishioka K, Moriya H, Hidaka S (2013) Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study. J Cardiovasc Pharmacol Ther 18:439–446
79. Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG (2011) Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology (Carlton) 16:290–298
80. Shigematsu T, Tokumoto A, Nakaoka A, Arisaka H (2011) Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia. Ther Apher Dial 15:176–184
81. Di Iorio B, Cucciniello E (2010) Lanthanum carbonate is not associated with QT interval modification in hemodialysis patients. Clin Pharmacol 2:89–93
82. Hutchison AJ, Barnett ME, Krause R, Siami GA, Lanthanum Carbonate Study G (2009) Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease stage 5 receiving hemodialysis. Clin Nephrol 71:286–295
83. Tonooka A, Uda S, Tanaka H, Yao A, Uekusa T (2015) Possibility of lanthanum absorption in the stomach. Clin Kidney J 8:572–575
84. Hara S, Fujimori A, Nishi S (2015) Clinicopathological characteristics of lanthanum deposition in the gastrointestinal tract of dialysis patients (abstract). J Am Soc Nephrol 26:279A
85. Valika AH, Jain D, Jaffe PE, Moeckel G, Brewster UC (2016) A nodular foreign body reaction in a dialysis patient receiving long-term treatment with lanthanum carbonate. Am J Kidney Dis 67(1):128–32
86. Black T, Philips G, Burbridge R (2013) Pharmacobezoar in a patient on an oral phosphate binder. Gastrointest Endosc 77:511–512
87. How PP, Anattiwong P, Mason DL, Arruda JA, Lau AH (2011) Phosphate-binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients. Hemodial Int 15:95–99
88. Pierce D, Hossack S, Robinson A, Zhang P, Martin P (2012) Assessment of pharmacodynamic equivalence and tolerability of lanthanum carbonate oral powder and tablet formulations: a single-center, randomized, open-label, 2-period crossover study in healthy subjects. Clin Ther 34(1290–300):e2
89. Hayashi H, Machida M, Sekine T, Yamaguchi H, Kiriyama T, Kumita S (2010) Beam-hardening artifacts on computed tomography images caused by lanthanum carbonate hydrate in a patient on dialysis. Jpn J Radiol 28:322–324
90. Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, Wolf M, Chertow GM (2015) A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3–5. Am J Kidney Dis 65:728–736
91. Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Block GA (2014) Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 9:543–552
92. Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, Whittier FC, Linfert DR, Galphin CM, Athreya BP, Nossuli AK, Chang IJ, Blumenthal SS, Manley J, Zeig S, Kant KS, Olivero JJ, Greene T, Dwyer JP, Collaborative Study G (2015) Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol 26:493–503
93. Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, Zeig S, Negoi DG, Hiremath AN, Blumenthal SS, Sika M, Niecestro R, Koury MJ, Ma KN, Greene T, Lewis JB, Dwyer JP, Collaborative Study G (2015) Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol 26:2578–2587
94. Lee CT, Wu IW, Chiang SS, Peng YS, Shu KH, Wu MJ, Wu MS (2015) Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study. J Nephrol 28:105–113
95. Yokoyama K, Hirakata H, Akiba T, Sawada K, Kumagai Y (2012) Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol 36:478–487
96. Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Chertow GM, Hirakata H (2014) A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transpl 29:1053–1060
97. Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, Kaplan M, Zeig S, Koury MJ, Blumenthal SS, Lewis JB, Collaborative Study G (2013) Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis 61:759–766
98. Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE, Collaborative Study G (2015) The phosphate binder ferric citrate and mineral metabolism and inflammatory markers in maintenance dialysis patients: results from prespecified analyses of a randomized clinical trial. Am J Kidney Dis 66:479–488
99. Cozzolino M, Funk F, Rakov V, Phan O, Teitelbaum I (2014) Preclinical pharmacokinetics, pharmacodynamics and safety of sucroferric oxyhydroxide. Curr Drug Metab 15:953–965
100. Chong E, Kalia V, Willsie S, Winkle P (2014) Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects. J Nephrol 27(6):659–666
101. Phan O, Maillard M, Funk F, Stehle JC, Burnier M (2015) 1d.08: effect of Pa21, a new iron-based phosphate binder on fibroblast growth factor 23 (Fgf23) and vascular calcifications in uremic rats. J Hypertens 33(Suppl 1):e16–e17
102. Wuthrich RP, Chonchol M, Covic A, Gaillard S, Chong E, Tumlin JA (2013) Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 8:280–289
103. Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM, Group PAS (2014) A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 86:638–647
104. Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM, Sucroferric Oxyhydroxide Study G (2015) Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transpl 30:1037–1046
105. Mudge DW, Johnson DW, Hawley CM, Campbell SB, Isbel NM, van Eps CL, Petrie JJ (2011) Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol 12:20
106. Block GA, Persky MS, Shamblin BM, Baltazar MF, Singh B, Sharma A, Pergola P, Smits G, Comelli MC (2013) Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease. Nephron Clin Pract 123:93–101
107. Savica V, Calo LA, Monardo P, Davis PA, Granata A, Santoro D, Savica R, Musolino R, Comelli MC, Bellinghieri G (2009) Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol 20:639–644
108. Akizawa T, Tsuruta Y, Okada Y, Miyauchi Y, Suda A, Kasahara H, Sasaki N, Maeda Y, Suzuki T, Matsui N, Niwayama J, Suzuki T, Hara H, Asano Y, Komemushi S, Fukagawa M (2014) Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial. BMC Nephrol 15:98
109. Oh MS, Uribarri J (2014) What can we learn from the saga of chitosan gums in hyperphosphatemia therapy? Clin J Am Soc Nephrol 9:967–970
110. Nakaki J, Yamaguchi S, Torii Y, Inoue A, Minakami S, Kanno T, Murakami M, Tsuzuki M, Mochizuki H, Suyama K, Miyamoto M (2013) Effect of fatty acids on the phosphate binding of TRK-390, a novel, highly selective phosphate-binding polymer. Eur J Pharmacol 714:312–317
111. Moustafa M, Lehrner L, Al-Saghir F, Smith M, Goyal S, Dillon M, Hunter J, Holmes-Farley R (2014) A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis. Int J Nephrol Renovasc Dis 7:141–152
112. Block GA, Brillhart SL, Persky MS, Amer A, Slade AJ (2010) Efficacy and safety of SBR759, a new iron-based phosphate binder. Kidney Int 77:897–903
113. Chen JB, Chiang SS, Chen HC, Obayashi S, Nagasawa M, Hexham JM, Balfour A, Junge G, Akiba T, Fukagawa M (2011) Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: a 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. Nephrology (Carlton) 16:743–750
114. Gschwind HP, Schmid DG, von Blanckenburg F, Oelze M, van Zuilen K, Slade AJ, Stitah S, Kaufmann D, Swart P (2014) Iron uptake and ferrokinetics in healthy male subjects of an iron-based oral phosphate binder (SBR759) labeled with the stable isotope (58)Fe. Metallomics 6:2062–2071
115. Tamagawa K, Nakayama-Imaohji H, Wakimoto S, Ichimura M, Kuwahara T (2010) Utilization of titanium oxide-like compound as an inorganic phosphate adsorbent for the control of serum phosphate level in chronic renal failure. J Med Invest 57:275–283
116. Schiavi SC, Tang W, Bracken C, O’Brien SP, Song W, Boulanger J, Ryan S, Phillips L, Liu S, Arbeeny C, Ledbetter S, Sabbagh Y (2012) Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol 23:1691–1700
117. Maccubbin D, Tipping D, Kuznetsova O, Hanlon WA, Bostom AG (2010) Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. Clin J Am Soc Nephrol 5:582–589
118. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW (2008) A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 3:1131–1138
119. El Borolossy R, El Wakeel LM, El Hakim I, Sabri N (2016) Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis. Pediatr Nephrol 31(2):289–296
120. Pelletier S, Roth H, Bouchet JL, Drueke T, London G, Fouque D, French P, Calcium Observatory i (2010) Mineral and bone disease pattern in elderly haemodialysis patients. Nephrol Dial Transpl 25:3062–3070
121. Tamura MK, Tan JC, O’Hare AM (2012) Optimizing renal replacement therapy in older adults: a framework for making individualized decisions. Kidney Int 82:261–269